reporting-nuclear-medicine-studies

name	reporting-nuclear-medicine-studies
description	Structures nuclear medicine and PET/CT interpretation with SUV measurement and staging correlation. Use when reading nuclear medicine studies, interpreting PET findings, or documenting radiotracer uptake.
tags	["reporting","radiology"]
metadata	{"author":"casemark","practice_areas":["Radiology","Diagnostic Imaging"],"document_types":["Report"],"skill_modes":["Reporting"]}

Reporting Nuclear Medicine Studies

Structures nuclear medicine and PET/CT interpretation with SUV measurement and staging correlation.

Why This Skill Exists

Nuclear medicine studies provide unique functional and metabolic information that complements anatomic imaging. PET/CT with 18F-FDG is the cornerstone of oncologic staging, treatment response assessment, and surveillance. Other nuclear medicine studies — bone scans, thyroid scans, V/Q scans, hepatobiliary scans, renal scans — each have specific interpretation criteria, quantitative thresholds, and reporting standards. Misinterpreting physiologic radiotracer uptake as pathology, failing to correlate PET findings with CT anatomy, or omitting SUV measurements undermines the clinical utility of these studies.

The ACR-SNMMI Practice Parameter for PET/CT and general nuclear medicine mandates structured reporting with quantitative measurements, clinical correlation, and explicit comparison with prior studies. The Deauville 5-point scale is the international standard for interim PET response in lymphoma, and the Lugano classification integrates PET findings into lymphoma staging. For PE evaluation, the PIOPED II criteria and modified PIOPED criteria define V/Q interpretation standards. This skill provides the systematic framework for interpreting and reporting nuclear medicine studies across all major exam types.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What nuclear medicine study is being interpreted? (Default: Identify — PET/CT, bone scan, thyroid scan, V/Q scan, renal scan, HIDA/hepatobiliary, MUGA, etc.)
2. What radiotracer was used? (Default: 18F-FDG for PET/CT — specify for other studies)
3. What is the clinical indication? (Default: Staging, restaging, treatment response, surveillance — obtain specific clinical question)
4. Are prior nuclear medicine studies available? (Default: No — obtain for comparison)
5. Is the patient's blood glucose level documented? (Default: Required for FDG PET — must be <200 mg/dL)
6. What is the patient's oncologic history/staging? (Default: Obtain cancer type, treatment history, current staging)
7. Was diagnostic CT performed concurrently or is this a low-dose attenuation-correction CT only? (Default: Verify CT technique)

Documents to Request

• Nuclear medicine images (all standard views and reconstructions)
• Blood glucose level at time of FDG injection
• Radiotracer type, dose, injection-to-scan time
• Prior nuclear medicine studies for comparison
• Recent cross-sectional imaging (CT, MRI) for correlation
• Oncologic staging history and treatment timeline
• Relevant tumor markers and clinical notes

---

Step 1: Technical Assessment

FDG PET/CT Technical Quality

Parameter	Standard	Impact if Suboptimal
Blood glucose	<200 mg/dL (ideally <150)	Elevated glucose competes with FDG; decreases tumor uptake, increases muscle uptake
Uptake time	60 ± 10 minutes	Inconsistent uptake times affect SUV comparability between studies
Patient fasting	≥4–6 hours	Non-fasting increases physiologic GI and muscle uptake
CT technique	Diagnostic vs. low-dose AC only	Low-dose CT limits anatomic correlation; document limitation
Misregistration	PET-CT alignment	Respiratory motion causes misregistration at diaphragm; note if findings are affected
Injection quality	Extravasation check	Extravasation at injection site reduces circulating activity; document and note impact

Other Nuclear Medicine Technical Factors

Study	Key Technical Factor
Bone scan	2–3 hour delay post-injection; adequate hydration and voiding
V/Q scan	Adequate Tc-99m MAA particles (200,000–700,000); Xe-133 or Tc-99m DTPA for ventilation
Thyroid scan	TSH level (elevated for whole-body I-131); iodine-free diet if I-131
Renal scan (MAG3)	Adequate hydration; Lasix timing for diuretic renogram
HIDA	Fasting ≥4 hours; morphine augmentation if needed

---

Step 2: PET/CT Interpretation — Systematic Approach

SUV Measurement Technique

Metric	Definition	Clinical Use
SUVmax	Maximum SUV within a VOI	Most commonly reported; highest single-voxel value
SUVpeak	Average SUV in a 1 cm³ sphere centered on hottest voxel	Less susceptible to noise than SUVmax
SUVmean	Average SUV across the entire VOI	Used in research; less common clinically
SULpeak	Lean-body-mass-corrected SUVpeak	Recommended for treatment response; normalizes for body composition
MTV	Metabolic tumor volume	Total volume of metabolically active tumor
TLG	Total lesion glycolysis (SUVmean × MTV)	Quantifies total metabolic burden

Physiologic FDG Uptake (Normal — Do Not Misinterpret)

Location	Pattern	Mimics
Brain	Intense cortical uptake	— (baseline reference)
Tonsillar/Waldeyer ring	Symmetric ring of uptake	Lymphoma (asymmetric = suspicious)
Vocal cords	Bilateral, symmetric, post-vocalization	Laryngeal tumor (unilateral = suspicious)
Myocardium	Variable (fasting state reduces)	Cardiac tumor (focal = suspicious)
GI tract (stomach, colon)	Variable physiologic; peristaltic pattern	GI malignancy (focal, intense = suspicious)
Urinary tract	Excreted FDG in collecting system, bladder	Urothelial tumor (wall-based uptake)
Bone marrow	Diffuse after chemotherapy or G-CSF	Marrow involvement (focal = suspicious)
Brown fat	Bilateral symmetric neck/supraclavicular	Lymphadenopathy (correlate with CT)

PET/CT Report Structure — Organ-System Review

1. Head/Neck: Brain, cervical lymph nodes, thyroid, salivary glands
2. Chest: Lungs, mediastinal/hilar lymph nodes, pleura, chest wall
3. Abdomen/Pelvis: Liver, spleen, adrenals, kidneys, GI tract, mesenteric/retroperitoneal lymph nodes, pelvis
4. Musculoskeletal: Bones (focal vs. diffuse uptake), joints (degenerative vs. inflammatory)
5. Skin/Subcutaneous: Injection site, skin metastases

---

Step 3: Disease-Specific Reporting Criteria

Lymphoma — Deauville 5-Point Scale (Lugano Classification)

Score	Uptake Level	Interpretation
1	No uptake	Complete metabolic response (CMR)
2	Uptake ≤ mediastinal blood pool	CMR
3	Uptake > mediastinal blood pool but ≤ liver	CMR (for most aggressive lymphomas)
4	Uptake moderately > liver	Partial metabolic response or progressive disease (context-dependent)
5	Uptake markedly > liver and/or new lesions	Progressive metabolic disease
X	New areas of uptake unlikely related to lymphoma	Document separately

Reference structures: Measure mediastinal blood pool SUV (aortic arch) and liver SUV (right lobe, avoiding vessels) as internal references at every timepoint.

Bone Scan Interpretation

Finding	Description	Significance
Focal increased uptake	Single or multiple discrete foci	Metastasis, fracture, infection, degenerative (correlate with history and location)
Superscan	Diffusely increased skeletal uptake with absent renal activity	Diffuse skeletal metastases (prostate, breast)
Flare response	Increased uptake on post-treatment scan → improves on subsequent scan	Healing response; not progression
Photopenic lesion	Cold defect	Purely lytic metastasis (myeloma, renal cell), avascular necrosis, radiation

V/Q Scan — Modified PIOPED II Criteria

Category	Criteria	PE Probability
Normal	No perfusion defects	<5%
Very low	Non-segmental perfusion defects; match defects with normal CXR	<10%
Low	Small subsegmental V/Q mismatch	10–30%
Intermediate	Difficult to categorize	30–70%
High	≥2 large segmental mismatched perfusion defects	>80%

---

Step 4: Report Structure

Standard Nuclear Medicine Report Format

Header: Patient demographics, study type, radiotracer, dose, injection-to-scan time, blood glucose (PET)

Clinical Indication: Specific clinical question with relevant history

Comparison: Prior studies with dates and modality

Technique: Radiotracer, dose, route, uptake time, CT parameters (diagnostic vs. low-dose), fasting status

Findings: Organ-system review with SUV measurements for significant findings; comparison with prior SUV values when available

Impression:

1. Most clinically significant finding addressing the clinical question
2. Disease-specific classification (Deauville score, Lugano response category)
3. Incidental findings with recommendations
4. Comparison summary with prior study

---

Step 5: Treatment Response Assessment

PET Response Criteria — PERCIST 1.0

Category	Criteria
CMR (Complete)	Complete resolution of FDG uptake in all lesions; no new FDG-avid lesions
PMR (Partial)	≥30% decrease in SULpeak of target lesion
SMD (Stable)	Does not meet CMR, PMR, or PMD criteria
PMD (Progressive)	≥30% increase in SULpeak or new FDG-avid lesions

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the radiotracer and technical quality documented (glucose, uptake time)?
2. Are SUV measurements provided for all significant findings?
3. Is physiologic uptake distinguished from pathology?
4. Is the appropriate disease-specific classification applied (Deauville, PERCIST)?
5. Are prior studies compared with SUV trending?

---

Quality Audit

• Radiotracer, dose, and injection-to-scan time are documented
• Blood glucose level is recorded for FDG PET studies
• CT technique (diagnostic vs. low-dose) is specified
• SUVmax is reported for all significant lesions
• Physiologic uptake is recognized and not over-interpreted
• Disease-specific scoring is applied (Deauville, PERCIST, modified PIOPED)
• Reference structure SUVs (mediastinal blood pool, liver) are documented for lymphoma
• Comparison with prior PET studies includes SUV trending
• New lesions are explicitly identified and flagged
• Incidental findings are managed per ACR recommendations
• Report addresses the specific clinical question in the impression
• Technical limitations (misregistration, extravasation, elevated glucose) are noted
• Bone scan flare response is considered in post-treatment context

---

Guidelines

1. Always document blood glucose level for FDG PET — studies performed with glucose >200 mg/dL have reduced sensitivity and should prompt consideration of rescanning.
2. Report SUVmax for all significant lesions; use SULpeak when applying PERCIST criteria for treatment response.
3. Correlate every PET finding with the CT component — FDG-avid findings without a CT correlate require further investigation, not dismissal.
4. Apply the Deauville 5-point scale for lymphoma interim and end-of-treatment PET; always report mediastinal blood pool and liver reference SUVs.
5. Recognize physiologic variants (brown fat, post-G-CSF marrow activation, GI peristalsis) to avoid false-positive interpretations.
6. For V/Q scans, use the modified PIOPED II criteria and provide a probability category — vague interpretations like "indeterminate" should prompt recommendation for CTA.
7. Compare uptake-time-matched studies when trending SUV; a 90-minute uptake-time PET is not directly comparable to a 60-minute study.